FDA Approval: Durvalumab with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer image

FDA Approval: Durvalumab with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer

By Leslie Fannon Zhang Content Strategy Manager, HealthTree Foundation Posted on: Nov 17, 2026 Medically reviewed by Jimena Vicencio, MD: Nov 17, 2026

On November 13, 2026, the U.S. Food and Drug Administration (FDA) approved a new combination for people with muscle-invasive bladder cancer (MIBC) who cannot or do not want cisplatin-based chemotherapy. The combination includes:

  • Durvalumab (Imfinzi, AstraZeneca) 

  • Enfortumab vedotin-ejfv (Padcev, Astellas Pharma and Pfizer) 

It is given as a neoadjuvant treatment. Neoadjuvant treatments are given before other treatments, typically surgery, to shrink the tumor. This combination is given before a radical cystectomy, which is surgery to remove the entire bladder and surrounding lymph nodes and tissues. After radical cystectomy, patients continue treatment with durvalumab alone. 

In the United States, there will be an estimated 84,530 people diagnosed with bladder cancer in 2026. About 1 in 4 will have MIBC. This means the tumor has spread into the bladder wall or beyond. Half of these patients cannot receive cisplatin-based chemotherapy because they already have damaged kidneys or other health problems. For this subset of people with MIBC, surgery has typically been the only treatment option, but the cancer often comes back. 

This new treatment combination reduced the risk of death by 42% compared to surgery alone, offering an important treatment option for patients with this aggressive type of MIBC.

Dr. Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center in an AstraZeneca press release pronounced his opinion on this approval: “This approval brings the first perioperative immunotherapy regimen where enfortumab vedotin is administered only in the neoadjuvant setting to patients with muscle-invasive bladder cancer who are not candidates for cisplatin-based chemotherapy. The results of VOLGA show a statistically significant and clinically meaningful improvement in both event-free and overall survival along with a manageable safety profile. Based on this, the VOLGA regimen has the potential to become a new standard of care in this curative-intent setting."

How does durvalumab with enfortumab treat MIBC?

Durvalumab is a type of immunotherapy called a PD-L1 inhibitor. It blocks a protein that cancer cells rely on to grow. It is used to treat many different cancers, including:

  • Bile duct and gallbladder cancer

  • Endometrial Cancer

  • Lung cancer

  • Liver cancer

  • Stomach cancer

Durvalumab has also been previously approved to treat non-muscle-invasive bladder cancer and in combination with chemotherapy for MIBC.

Enfortumab vedotin is an antibody-drug conjugate. It targets Nectin-4, an adhesion protein found on the surface of cells. Once it attaches to the cell, it releases a platinum-free chemotherapy directly to the cancer cell.  

VOLGA: The study that led to the durvalumab with enfortumab vedotin approval

This approval was based on the phase 3 VOLGA clinical trial. This trial treated 695 patients with MIBC. The participants had to be:

  • Eligible for a radical cystectomy (surgery that removes the entire urinary bladder, nearby lymph nodes, and adjacent pelvic organs)

  • Ineligible or refused cisplatin-based chemotherapy

There were three treatment groups in the clinical trial. 

  • One group received neoadjuvant durvalumab and enfortumab vedotin before radical cystectomy followed by durvalumab alone

  • One group only received a radical cystectomy

  • One group received another investigational treatment combination

Compared to surgery alone, the group that received durvalumab with enfortumab vedotin had better outcomes. The median event-free survival was not reached in the durvalumab group, meaning more than half of the participants had not had changes to their illness after treatment began. In comparison, in the surgery alone group, the median event-free survival was 12.1 months. Median overall survival was not reached in either group. This means that more than half of participants in each group were still alive when the data was collected. 

What are the common side effects of durvalumab and enfortumab vedotin?

The most common side effects of durvalumab with enfortumab vedotin were:

  • Increased liver enzymes AST or ALT levels (AST or ALT). AST and ALT are liver enzymes. 

  • Decreased hemoglobin

  • Rash

  • Increased creatinine

  • Itching

  • Decreased calcium

  • Increased lipase

  • Increased potassium

  • Urinary tract infection

Next steps for people living with MIBC

If you or a loved one has been recently diagnosed with MIBC and you are not eligible for platinum-based chemotherapy, ask your healthcare team about this treatment combination or ongoing clinical trials. 

Questions to ask your care team about durvalumab and enfortumab vedotin

Consider asking your care team the following questions about durvalumab with enfortumab vedotin:

  • Based on my health history, am I eligible for platinum-based chemotherapy? 

  • How does this treatment combination compare to other options available to me?

  • Are there any clinical trials I should consider for my care?

SOURCES:

Medically reviewed by

Healthtree contact Jimena Vicencio

Jimena Vicencio

Jimena is a medical doctor currently studying a bachelor in journalism.

Jimena is a member of the HealthTree Writing team. With an MD background and currently pursuing a bachelor's degree in journalism, she combines her medical knowledge with a storyteller’s heart to make complex healthcare topics accessible to everyone. Driven by a deep belief that understanding health is a universal right, she is passionate about empowering individuals to take control of their well-being.